Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608894 · ClinicalTrials.gov registry record · Phase 2
LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
A Phase 2 study, sponsored by Veloxis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00608894 is a Phase 2 study that was terminated before completion, run by Veloxis Pharmaceuticals. The registered enrollment target is 13 participants.
The verdict
NCT00608894, a Phase 2 study, was terminated before completion, sponsored by Veloxis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine, each in combination with prednisone, for the treatment of autoimmune hepatitis (AIH).
Interventions
- DRUG Azathioprine
- DRUG LCP-Tacro (tacrolimus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608894
The ClinicalTrials.gov registry entry for NCT00608894 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veloxis Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azathioprine is the first listed.
NCT00608894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00608894 about?
NCT00608894 is a clinical study titled "LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis". An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine, each in combination with prednisone, for the treatment of autoimmune hepatitis (AIH).
What is the current status of trial NCT00608894?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2007-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00608894?
The interventions under investigation include: Azathioprine (DRUG), LCP-Tacro (tacrolimus) (DRUG).
Who is sponsoring clinical trial NCT00608894?
This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.